Combined inhibition of SHP2 and CXCR1/2 promotes antitumor T-cell response in NSCLC

KH Tang, S Li, A Khodadadi-Jamayran, J Jen, H Han… - Cancer discovery, 2022 - AACR
Abstract SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in
multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in …
被引用次数：78 相关文章

Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

KH Tang, S Li, A Khodadadi-Jamayran, J Jen, H Han… - bioRxiv, 2021 - biorxiv.org
Clinical trials of SHP2 inhibitors (SHP2i) alone and in various combinations are ongoing for
multiple tumors with over-activation of the RAS/ERK pathway. SHP2 plays critical roles in …

Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.

KH Tang, S Li, A Khodadadi-Jamayran, J Jen… - Cancer …, 2021 - europepmc.org
Abstract SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in
multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in …
[HTML] nih.gov

[HTML][HTML] Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC

KH Tang, S Li, A Khodadadi-Jamayran, J Jen… - Cancer …, 2022 - ncbi.nlm.nih.gov
Abstract SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in
multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in …

Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC

KH Tang, S Li, A Khodadadi-Jamayran… - Cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in multiple
tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in normal cell …

Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

KH Tang, S Li, A Khodadadi-Jamayran, J Jen, H Han… - 2021 - europepmc.org
Clinical trials of SHP2 inhibitors (SHP2i) alone and in various combinations are ongoing for
multiple tumors with over-activation of the RAS/ERK pathway. SHP2 plays critical roles in …
[HTML] nih.gov

[HTML][HTML] Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

KH Tang, S Li, A Khodadadi-Jamayran, J Jen… - Cancer …, 2022 - ncbi.nlm.nih.gov
Abstract SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in
multiple tumors with over-activation of the RAS/ERK pathway. SHP2 plays critical roles in …